Effect of penclomedine (NSC-338720) on telomere fusions, chromatin blebbing, and cell viability with and without telomerase activity and abrogated p53 function

Biochemical Pharmacology

Volumn 53, Issue 3, 1997, Pages 409-415

  Pandita, Tej K ^a,e   Benvenuto, John A ^b   Shay, Jerry W ^c   Pandita, Raj K ^d   Rakovitch, Eileen ^a   Geard, Charles R ^a   Antman, Karen H ^a   Newman, Robert A ^b  

^a The New York Presbyterian Hospital   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e Center for Radiological Research   (United States)

Author keywords

blebbing; chromosome end associations; p53; penclomedine; telomerase; tumor

Indexed keywords

ANTINEOPLASTIC AGENT; PENCLOMEDINE; PROTEIN P53; PYRIDINE DERIVATIVE; TELOMERASE;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CHROMATIN STRUCTURE; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; MITOSIS INDEX; PRIORITY JOURNAL; TELOMERE; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CHROMATIN; GENES, P53; HELA CELLS; HUMANS; MITOTIC INDEX; PICOLINES; TELOMERASE; TELOMERE;

EID: 0031054236     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00766-6     Document Type: Article

References (37)

1. Muller HJ, The remaking of chromosomes. The Collecting Net 8: 182-195, 1938.
2. McClintock B, The stability of broken ends of chromosomes of Zea Mays. Genetics 26: 234-282, 1941.
3. Zakian VA, Structure and function of telomeres. Annu Rev Genet 23: 579-604, 1989.
4. Greider C, Telomeres. Curr Opin Cell Biol 3: 444-451, 1991.
5. Blackburn EH, Structure and function of telomeres. Nature 350: 569-573, 1991.
6. n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 85: 6622-6626, 1988.
7. Grieder C and Blackburn E, Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43: 405-413, 1985.
8. Blackburn EH, Telomerases. Annu Rev Biochem 61: 113-129, 1993.
9. Counter CM, Hirte HW, Baccheri S and Harley CB, Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 91: 2900-2904, 1994.
10. deLange T, Activation of telomerase in a human tumor. Proc Natl Acad Sci USA 91: 2882-2885, 1994.
11. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weintrich SL and Shay JW, Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2100-2115, 1994.
12. Broccoli D, Young JW and deLange T, Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 92: 9082-9086, 1995.
13. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA and Shay JW, Correlating telomerase activity with human neuroblastoma outcome. Nature Med 1: 249-255, 1995.
14. Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW, Ishoika S and Yamakido M, Activation of telomerase in human lymphocytes and hematopoietic cells. J Immunol 155: 3711-3715, 1995.
15. Hiyama K, Hiyama E, Ishoika S, Yamakido M, Inai K, Gazdar AF, Piatyszek MA and Shay TW, Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 87: 895-902, 1995.
16. Piatyszek MA, Kim NW, Weinrich SL, Hiyama K, Hiyama E, Wright WE and Shay JW, Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 17: 1-15, 1995.
17. Prowse KR and Grieder CW, Development and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA 92: 4818-4822, 1995.
18. Tahara H, Nakanishi Y, Kitamot M, Nakashio R, Shay JW, Tahara E, Kajiyama G and Ide T, Telomerase activity in human liver tissue: Comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 55: 2734-2736, 1995.
19. Shay JW, Werbin H and Wright WE, Telomeres and telomerase in human leukemias. Leukemia 10: 1255-1251, 1966.
20. Pandita TK, Hall EJ, Hei TK, Piatyszek MA, Wright WE, Piao CQ, Pandita RK, Dewey JW, Geard CR, Kastan MB and Shay JW, Chromosome end-to-end associations and telomerase activity during cancer progression in human cells after treatment with α-particles simulating radon progeny. Oncogene, 13: 1423-1430, 1996.
21. Holt SE, Wright WE and Shay JW, Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 16: 2932-2939, 1996.
22. Benvenuto JA, Hittelman WN, Zwelling LA, Plunkett W, Pandita TK, Farquhar D and Newman RA, Biochemical pharmacology of penclomedine (NSC-338720). Biochem Pharmacol 50: 1157-1164, 1995.
23. Plowman J, Harrison SD, Dykes DJ, Paull KD, Narayanan VL, Tobol HK, Martin J and Griswold DP Jr, Preclinical antitumor activity of an α-picoline derivative, penclomedine (NSC 338720), on human murine tumors. Cancer Res 49: 1909-1915, 1989.
24. Harrison SD Jr, Plowman J, Dykes DJ, Wand WR and Griswold DP Jr, Preclinical antitumor activity of penclomedine in mice: Cross-resistance, schedule dependence, and oral activity against tumor xenograft in brain. Cancer Res 51: 1979-1983, 1991.
25. Pandita TK, Gregoire V, Dhingra K and Hittelman WN, Effect of chromosome size on aberration levels caused by gamma radiation as detected by fluorescence in situ hybridization. Cytogenet Cell Genet 67: 94-101, 1994.
26. Keissis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L and Cho KR, Human papillomavirus 16E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci USA 90: 3988-3992, 1993.
27. Pandita TK, Assessment of the mutagenic potential of a fungicide, bavistin, using multiple assays. Mutant Res 204: 627-643, 1988.
28. Pandita TK, Effect of temperature variation of sister chromatid exchange frequency in cultured human cells. Hum Genet 63: 189-190, 1983.
29. Pandita TK, Pathak S and Geard CR, Chromosome end associations, telomeres and telomerase activity in ataxia telangiectasia cells. Cytogenet Cell Genet 71: 86-93, 1996.
30. Pandita TK and DeRubeis D, Spontaneous amplification of interstitial telomeric bands in Chinese hamster ovary cells. Cytogenet Cell Genet 68: 95-101, 1995.
31. Wright WE, Shay JW and Piatyszek MA, Modification of a telomeric repeat amplification protocol (TRAP) results in increased reliability, linearity and sensitivity. Nucleic Acids Res 23: 3794-3795, 1995.
32. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM, Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937-948, 1992.
33. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD, Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935, 1992.
34. Feng J, Funk WD, Wang S-S, Weinrich SL, Avilion AA, Chiu C-P, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW and Villeponteau B, The RNA component of human telomerase. Science 269: 1236-1241, 1995.
35. Wright WE, Brasiskyte D, Piatyszek MA and Shay JW, Experimental elongation of telomeres in immortal human cell extends the life span of immortal cell hybrids. EMBO J 15: 1734-1741, 1996.
36. Sharma HW, Sokoloski JA, Perez JR, Maltese JY, Sartorelli AC, Stein CA, Nichols G, Khaled Z, Telang NT and Narayanan R, Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci USA 92: 12434-12346, 1995.
37. Zhang W, Piatyszek MA, Estey E, Kobayashi T, Andreff M, Deisseroth AB, Wright WE and Shay JW, Inhibition of telomerase by differentiation-inducing agents. Clin Cancer Res 2: 799-803, 1996.